In vitro survival of MCF-7 breast cancer cells following combined treatment with ionizing radiation and mitoxantrone-mediated photodynamic therapy

Photodiagnosis and Photodynamic Therapy

Volumn 10, Issue 1, 2013, Pages 72-78

  Sazgarnia, Ameneh ^a   Montazerabadi, Ali Reza ^b   Bahreyni Toosi, Mohammad Hossein ^a   Ahmadi, Amirhossein ^c   Aledavood, Amir ^d  

^a MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c MAZANDARAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Ionizing radiation; MCF 7 breast cancer; Mitoxantrone; Photodynamic therapy

Indexed keywords

MITOXANTRONE;

ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL DEATH; CELL STRAIN MCF 7; CELL SURVIVAL; CONTROLLED STUDY; DRUG EFFECT; HUMAN; HUMAN CELL; IN VITRO STUDY; IONIZING RADIATION; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RADIATION DOSE;

ANTINEOPLASTIC AGENTS; CELL SURVIVAL; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MCF-7 CELLS; MITOXANTRONE; NEOPLASMS, EXPERIMENTAL; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; RADIOTHERAPY; TREATMENT OUTCOME;

EID: 84875401705     PISSN: 15721000     EISSN: 18731597     Source Type: Journal    
DOI: 10.1016/j.pdpdt.2012.06.001     Document Type: Article

References (59)

1. Theakston F. World health statistics 2008. Breast cancer: mortality and screening 2008, WHO Press, France.
2. Parkin D.M., Pisani P., Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1990. International Journal of Cancer 1999, 80:827-841.
3. Dougherty T.J., Gomer C.J., Henderson B.W., et al. Photodynamic therapy. Journal of the National Cancer Institute 1998, 90:889-905.
4. Dennis E.J., Dolmans G.J., Fukumura D., Jain R.K. Photodynamic therapy for cancer. Nature Reviews Cancer 2003, 3:380-387.
5. Kessel D. Photodynamic therapy: from the beginning. Photodiagnosis and Photodynamic Therapy 2004, 1:3-7.
6. Brown S.B., Brown E.A., Walker I. The present and future role of photodynamic therapy in cancer treatment. Lancet Oncology 2004, 5:497-508.
7. Patrice T. Photodynamic therapy comprehensive series in photochemistry and photobiology 2003, vol. 2. The Royal Society of Chemistry, Cambridge.
8. Henderson B.W., Dougherty T.J. How does photodynamic therapy work?. Photochemistry and Photobiology 1992, 55:145-157.
9. Valko M., Rhodes C.J., Moncol J., Izakovic M., Mazur M. Free radicals, metals and antioxidants in oxidative stress-induced cancer. Chemico-Biological Interactions 2006, 160:1-40.
10. Pastor N., Weinstein H., Jamison E., Brenowitz M. A detailed interpretation of OH radical footprints in a TBP-DNA complex reveals the role of dynamics in the mechanism of sequence-specific binding. Journal of Molecular Biology 2000, 304:55-68.
11. Plaetzer K., Kiesslich T., Oberdanner C.B., Krammer B. Apoptosis following photodynamic tumor therapy: induction, mechanisms and detection. Current Pharmaceutical Design 2005, 11:1151-1165.
12. Bashkatov A.N., Genina E.A., Kochubey V.I., Tuchin V.V. Optical properties of human skin, subcutaneous and mucous tissues in the wavelength range from 400 to 2000nm. Journal of Physics D: Applied Physics 2005, 38:2543-2555.
13. Jassem J., Begg A.C., Stewart F., Bartelink H. Combined chemotherapy and radiotherapy. Oxford textbook of oncology 1995, 811-823. Oxford University Press, Oxford. M. Peckham, H.M. Pinedo, U. Veronesi (Eds.).
14. Early Breast Cancer Trialists' Collaborative Group Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet 2005, 365:1687-1717.
15. Toledano A., Azria D., Garaud P., et al. Phase III trial of concurrent or sequential adjuvant chemoradiotherapy after conservative surgery for early-stage breast cancer: final results of the ARCOSEIN trial. Journal of Clinical Oncology 2007, 25:405-410.
16. Valagussa P., Zambetti M., Biasi S., Moliterni A., Zucali R., Bonadonna G. Cardiac effects following adjuvant chemotherapy and beast irradiation in operable breast cancer. Annals of Oncology 1994, 5:209-216.
17. Dun F.E. Biologic and biochemical effects of mitoxantrone. Seminars in Oncology 1984, 11(3 Suppl. 1):3-10.
18. Harker W.G., Slade D.L., Dalton W.S., Meltzer P.S., Trent J.M. Multidrug resistance in mitoxantrone-selected HL-60 leukemia cells in the absence of P-glycoprotein overexpression. Cancer Research 1989, 49:4542-4549.
19. Lenk H., Müller U., Tanneberger S. Mitoxantrone: mechanism of action, antitumor activity, pharmacokinetics, efficacy in the treatment of solid tumors and lymphomas, and toxicity. Anticancer Research 1987, 7:1257-1264.
20. Benjamin R.S. Rationale for the use of mitoxantrone in the older patient: cardiac toxicity. Seminars in Oncology 1995, 22:11-13.
21. Kapuscinski J., Darzynkiewicz Z., Traganos F., Melamed M.R. Interaction of a new antitumor agent, 1,4-dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]-9,10-anthracenedione, with nucleic acids. Biochemical Pharmacology 1981, 30:231-240.
22. Montazerabadi A.R., Sazgarnia A., Bahreyni-Toosi M.H., Ahmadi A., Shakeri Zadeh A., Aledavood A. Mitoxantrone as a prospective photosensitizer for photodynamic therapy of breast cancer. Photodiagnosis and Photodynamic Therapy 2012, 9:46-51.
23. Colasanti A., Kisslinger M., Quarto M., Riccio P. Combined effects of radiotherapy and photodynamic therapy on an in vitro human prostate model. Acta Biochimica Polonica 2004, 51:1039-1046.
24. Prinsze C., Penning L.C., Dubbelman T.M., VanSteveninck J. Interaction of photodynamic treatment and either hyperthermia or ionizing radiation and of ionizing radiation and hyperthermia with respect to cell killing of L929 fibroblasts, Chinese hamster ovary cells, and T24 human bladder cells. Cancer Research 1992, 52:117-120.
25. Haridasan P.P., Pillai P.M., Tripathi R.M., Puranik V.D. Occupational radiation exposure due to norm in a rare-earth compounds production facility. Radiation Protection Dosimetrys 2008, 131:217-221.
26. Emami B., Lyman J., Brown A., et al. Tolerance of normal tissue to therapeutic irradiation. International Journal of Radiation Oncology, Biology, Physics 1991, 21:109-122.
27. Dörr W., Hendry J.H. Consequential late effects in normal tissues. Radiotherapy and Oncology 2001, 61:223-231.
28. Denham J.W., Hauer-Jensen M., Peters L.J. Is it time for a new formalism to categorize normal tissue radiation injury?. International Journal of Radiation Oncology Biology Physics 2001, 50:1105-1106.
29. Hall E.J., Giaccia A.J. Radiobiology for the radiologist 2006, Lippincott Williams & Wilkins, Philadelphia. 6th ed.
30. Adamowicz K., Marczewska M., Jassem J. Combining systemic therapies with radiation in breast cancer. Cancer Treatment Reviews 2009, 35:409-416.
31. Bump E.A., Malaker K. Radioprotectors: chemical, biological and clinical perspective 1998, CRC Press, Florida.
32. DeVita V.T., Hellman S., Rosenberg S.A. Cancer: principle and practice of oncology 2001, J.B. Lippincott, Philadelphia. 6th ed.
33. Hall E.J. Radiobiology for the radiologist 2000, J.B. Lippincott, Philadelphia. 5th ed.
34. John M., Flam M., Legha S., Phillips T. Chemoradiation: an integrated approach to cancer treatment 1995, J.B. Lippincott, Philadelphia. 1st ed.
35. McGinn C.G., Shewach D.S., Lawrence T.S. Radiosensitizing nucleotides. Journal of the National Cancer Institute 1996, 88:1193-1203.
36. Mateos S., Hajji N., Pastor N., Cortés F. Modulation of radiation response by inhibiting topoisomerase II catalytic activity. Mutation Research 2006, 599:105-115.
37. Burden D.A., Osheroff N. Mechanism of action of eukaryotic topoisomerase II and drugs targeted to the enzyme. Biochimica et Biophysica Acta 1998, 1400:139-154.
38. Berger J.M. Structure of DNA topoisomerases. Biochimica et Biophysica Acta 1998, 1400:3-18.
39. Azarova A.M., Lyu Y.L., Lin C.P., et al. From the cover: roles of DNA topoisomerase II isozymes in chemotherapy and secondary malignancies. Proceedings of the National Academy of Sciences of the United States of America 2007, 104:11014-11019.
40. Painter R.B., Young B.R. Radiosensitivity in ataxia telangiectasia: a new explanation. Proceedings of the National Academy of Sciences of the United States of America 1980, 77:7315-7317.
41. Obe G., Johannes C., Schulte-Frohlinde D. DNA double-strand breaks induced by sparsely ionizing radiation and endonucleases as critical lesions for cell death, chromosomal aberrations, mutations and oncogenic transformation. Mutagenesis 1992, 7:3-12.
42. Iliakis G. The role of DNA double strand breaks in ionizing radiation-induced killing of eukaryotic cells. Bioessays 1991, 13:641-648.
43. Vibet S., Mahéo K., Goré J., Dubois P., Bougnoux P., Chourpa I. Differential subcellular distribution of mitoxantrone in relation to chemosensitization in two human breast cancer cell lines. Drug Metabolism and Disposition: The Biological Fate of Chemicals 2007, 35:822-828.
44. Blanz J., Mewes K., Ehninger G., et al. Evidence for oxidative activation of mitoxantrone in human, pig and rat. Drug Metabolism and Disposition: The Biological Fate of Chemicals 1991, 19:871-880.
45. Kurose A., Tanaka T., Huang X., et al. Assessment of ATM phosphorylation on Ser-1981 induced by DNA topoisomerase I and II inhibitors in relation to Ser-139-histone H2AX phosphorylation, cell cycle phase, and apoptosis. Cytometry A 2005, 68:1-9.
46. MacPhail S.H., Banáth J.P., Yu T.Y., Chu E.H., Lambur H., Olive P.L. Expression of phosphorylated histone H2AX in cultured cell lines following exposure to X-rays. International Journal of Radiation Biology 2003, 79:351-358.
47. Huang X., Traganos F., Darzynkiewicz Z. DNA damage induced by DNA topoisomerase I- and topoisomerase II-inhibitors detected by histone H2AX phosphorylation in relation to the cell cycle phase and apoptosis. Cell Cycle 2003, 2:614-619.
48. Rosenberg L.S., Carvlin M.J., Krugh T.R. The antitumor agent mitoxantrone binds cooperatively to DNA: evidence for heterogeneity in DNA conformation. Biochemistry 1986, 25:1002-1008.
49. Fisher G.R., Patterson L.H. Lack of involvement of reactive oxygen in the cytotoxicity of mitoxantrone, CI941 and ametantrone in MCF-7 cells-comparison with doxorubicin. Cancer Chemotherapy and Pharmacology 1992, 30:451-458.
50. Kapuscinski J., Darzynkiewicz Z. Relationship between the pharmacological activity of antitumor drugs ametantrone and mitoxantrone and their ability to condense nucleic acids. Proceedings of the National Academy of Sciences of the United States of America 1986, 83:6302-6306.
51. Crooke S.T., Duvernay V.H., Mong S. Molecular pharmacology of anthracyclines, molecular actions and targets for cancer chemotherapeutic agents 1981, Academic Press, New York, pp. 137-145.
52. Lown J.W., Morgan A.R., Yen S.F., Wang Y.H., Wilson W.D. Characteristics of the binding of the anticancer reagents mitoxantrone and ametantrone and related structures to deoxyribonucleic acids. Biochemistry 1985, 24:4028-4035.
53. Fox K.R., Waring M.J., Brown J.R., Neidle S. DNA sequence preferences for the anticancer drug mitoxantrone and related anthraquinones revealed by Dnase I footprinting. FEBS Letters 1986, 202:289-294.
54. Kapuscinski J., Darzynkiewicz Z. Condensation of nucleic acids by intercalating aromatic cations. Proceedings of the National Academy of Sciences of the United States of America 1984, 81:7368-7372.
55. Islam S.A., Neidle S., Gandecha B.M., Partridge M., Patterson L.H., Brown J.R. Comparative computer graphics and solution studies of the DNA interaction of substituted anthraquinones based on doxorubicin and mitoxantrone. Journal of Medicinal Chemistry 1985, 28:857-864.
56. Capranico G., De Isabella P., Tinelli S., Bigioni M., Zunino F. Similar sequence specificity of mitoxantrone and VM-26 stimulation of in vitro DNA cleavage by mammalian DNA topoisomerase II. Biochemistry 1993, 32:3038-3046.
57. Smart D.J., Halicka H.D., Schmuck G., Traganos F., Darzynkiewicz Z., Williams G.M. Assessment of DNA double-strand breaks and γH2AX induced by the topoisomerase II poisons etoposide and mitoxantrone. Mutation Research 2008, 641:43-47.
58. Davies S.M., Davies S.L., Hall A.G., Hickson I.D. Isolation and partial characterisation of a mammalian cell mutant hypersensitive to topoisomerase II inhibitors and X-rays. Mutation Research 1990, 235:111-118.
59. Ramakrishnan N., Clay M.E., Friedman L.R., Antunez A.R., Oleinick N.L. Post-treatment interactions of photodynamic and radiation induced cytotoxic lesions. Photochemistry and Photobiology 1990, 52:555-559.